Marshall Wace North America’s Rigel Pharmaceuticals RIGL Stock Holding History

Marshall Wace North America’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,149	Closed	-$82K	–	1509
2019 Q2	$82K	Sell	3,149 -324	-9%	-$7.31K	﹤0.01%	1075
2019 Q1	$89K	Buy	+3,473	New	+$79.4K	﹤0.01%	1135
2018 Q4	–	Sell	-36,313	Closed	-$1.17M	–	1606
2018 Q3	$1.17M	Sell	36,313 -381,479	-91%	-$11.5M	0.01%	584
2018 Q2	$11.8M	Buy	417,792 +115,172	+38%	+$4.1M	0.07%	290
2018 Q1	$10.7M	Sell	302,620 -25,468	-8%	-$1.02M	0.05%	380
2017 Q4	$12.7M	Buy	328,088 +59,927	+22%	+$2.28M	0.07%	323
2017 Q3	$8.04M	Buy	268,161 +69,342	+35%	+$1.69M	0.05%	425
2017 Q2	$5.96M	Buy	198,819 +986	+0.5%	+$27K	0.04%	451
2017 Q1	$5.93M	Buy	+197,833	New	+$5.04M	0.05%	358
2013 Q3	–	Sell	-7,512	Closed	-$251K	–	691
2013 Q2	$251K	Buy	+7,512	New	+$340K	0.02%	374

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace North America's RIGL Position: Q3 2019 in Review

Marshall Wace North America sold out of Rigel Pharmaceuticals (RIGL) in Q3 2019, closing a stake of 3,149 shares — an estimated $82K sold.

Marshall Wace North America first reported a position in RIGL in Q2 2013 and held it in 10 quarters. The position peaked at $12.7M in Q4 2017. 131 funds tracked by Wall St. Rank hold RIGL as of Q3 2019.

Marshall Wace North America reported no remaining Rigel Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Marshall Wace North America sold 3,149 Rigel Pharmaceuticals shares in Q3 2019, an estimated $82K.
Marshall Wace North America first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Marshall Wace North America's Rigel Pharmaceuticals position peaked at $12.7M in Q4 2017.
131 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2019.

Based on Marshall Wace North America's 13F filing for Q3 2019, filed 14 Nov 2019.